Combining COX-2 Inhibitors with Aromatase Inhibitors in Breast Cancer
Author Information
Author(s): Bundred N J, Barnes N L P
Primary Institution: South Manchester University Hospital
Hypothesis
The combination of COX-2 inhibitors and aromatase inhibitors may be particularly effective in treating breast cancer.
Conclusion
Combining COX-2 inhibitors with aromatase inhibitors may reduce overall disease recurrence in breast cancer patients.
Supporting Evidence
- COX-2 is overexpressed in several epithelial tumors, including breast cancer.
- High COX-2 expression is associated with poor prognosis in breast cancer patients.
- Combining COX-2 inhibitors with aromatase inhibitors may enhance treatment effectiveness.
Takeaway
This study suggests that using two types of medicine together might help people with breast cancer live longer without their cancer coming back.
Methodology
The study involved preclinical and clinical evidence examining the effects of COX-2 inhibitors and aromatase inhibitors on breast cancer.
Potential Biases
Potential bias may arise from the limited sample size and the focus on specific patient demographics.
Limitations
The study does not provide long-term data on the safety of COX-2 inhibitors, particularly regarding cardiovascular risks.
Participant Demographics
The study primarily involved postmenopausal women with advanced breast cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website